RTX (RTX) Q1 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 24/25 earnings summary
6 Jun, 2025Executive summary
Q1 2024/25 revenue increased 23% year-over-year to 101 DKKm, driven by strong Enterprise segment performance and resumed customer orders after inventory reductions.
Gross margin improved to 50.8% from 38.9% in Q1 2023/24, reflecting favorable product mix and cost optimization.
EBITDA loss narrowed to -9.4 DKKm from -30.5 DKKm year-over-year, mainly due to higher revenue and improved margins.
Order intake improved, especially in the Enterprise segment, but order horizons remain short at 3–6 months, limiting full-year visibility.
New CEO Henrik Mørck Mogensen to start March 2025.
Financial highlights
Revenue: 101 DKKm in Q1 2024/25 vs. 82 DKKm in Q1 2023/24 (+23%).
Gross margin: 50.8% in Q1 2024/25 vs. 38.9% in Q1 2023/24 (+11.9 pp).
EBITDA: -9.4 DKKm in Q1 2024/25 vs. -30.5 DKKm in Q1 2023/24.
EBIT: -15.6 DKKm (Q1 2023/24: -41.2 DKKm).
Net liquidity: 97 DKKm at Q1 end, down from 116 DKKm year-over-year.
Outlook and guidance
FY 2024/25 revenue guidance maintained at 490–520 DKKm.
EBITDA expected between 0 and 20 DKKm; EBIT between -35 and -15 DKKm.
Gross margin for the full year expected to be higher than last year, supported by product mix and cost optimization.
Orderbook visibility remains short at 3–6 months, but order pipeline is building up.
Main uncertainties include macroeconomic volatility, customer inventory replenishment, and short order horizons.
Latest events from RTX
- Revenue up 7% to DKK 108m, with strong Healthcare and ProAudio growth, margin up to 54.9%.RTX
Q1 25/262 Feb 2026 - Revenue up 7% year-over-year, gross margin and liquidity improved, guidance maintained.RTX
Q1 25/2629 Jan 2026 - Q3 revenue and margin improved, but outlook cut amid weak demand and short order cycles.RTX
Q3 23/2423 Jan 2026 - Revenue up 23% and gross margin at 51%, led by Enterprise; outlook limited by short order horizons.RTX
Q1 24/259 Jan 2026 - Revenue up 10%, gross margin at 50%-51%, EBITDA surged, and outlook remains strong.RTX
Q4 24/2529 Nov 2025 - Double-digit revenue growth and margin expansion achieved, with strong outlook for 2025/26.RTX
Q4 24/2529 Nov 2025 - Strong revenue and margin growth led to raised guidance and a DKK 20m share buyback.RTX
Q3 24/2523 Nov 2025 - Revenue and profit fell significantly amid high inventories and uncertainty; outlook remains cautious.RTX
Q4 23/2421 Oct 2025 - Enterprise and Healthcare growth drove strong H1 results, but tariff risks remain.RTX
Q2 24/255 Jun 2025